Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes

We aimed to identify metabolites to predict patients’ response to glucose lowering treatment during the first 5 years after detection of type 2 diabetes. Metabolites were measured by GC–MS in baseline samples from 346 screen-detected type 2 diabetes patients in the ADDITION-NL study. The response to...

Descripción completa

Detalles Bibliográficos
Autores principales: den Ouden, Henk, Pellis, Linette, Rutten, Guy E. H. M., Geerars-van Vonderen, Ilse K., Rubingh, Carina M., van Ommen, Ben, van Erk, Marjan J., Beulens, Joline W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703625/
https://www.ncbi.nlm.nih.gov/pubmed/26770180
http://dx.doi.org/10.1007/s11306-015-0930-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703625/
https://www.ncbi.nlm.nih.gov/pubmed/26770180
http://dx.doi.org/10.1007/s11306-015-0930-4

Ejemplares similares